Initial Study Sample Clauses

Initial Study. A study of a Completed Application conducted by the Transmission Provider (in coordination with the affected Transmission Owner(s)) in accordance with Section 19 or Section 32 of the Tariff. Either the Interconnection Customer or the Interconnected Transmission Owner; Interconnected Entities shall mean both of them. The Transmission Owner to whose transmission facilities or distribution facilities Customer Interconnection Facilities are, or as the case may be, a Customer Facility is, being directly connected. When used in an Interconnection Construction Service Agreement, the term may refer to a Transmission Owner whose facilities must be upgraded pursuant to the Facilities Study, but whose facilities are not directly interconnected with those of the Interconnection Customer.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Initial Study. In the Initial Study, ICF will disclose each of the CEQA environmental topics to determine which would require additional discussion in the focused EIR, and which would present no change from what was previously analyzed in the ConnectMenlo EIR. For efficiency and consistency with other City documents, the Initial Study will follow the same format as the 1125 O’Brien Drive Project Initial Study.  Aesthetics – Aesthetic impacts were determined to be less than significant in the ConnectMenlo Draft EIR. The Project would include increased development intensity; therefore, the buildings would have more mass, bulk, height, lighting, and/or glare, resulting in potentially greater visual impacts. Upon receipt of site plans, building elevations, and/or visual simulations (if available) prepared by the Project Sponsor, ICF will determine whether the Project would result in conflicts with existing plans and policies protecting aesthetic resources, as compared to what was analyzed in the ConnectMenlo EIR. However, it is not expected that impacts would be greater than those previously analyzed.  Agricultural and Forestry Resources – No agricultural or forestry resources currently exist at the Project site. Therefore, no impacts would occur.  Air Quality – It is anticipated that all of the air quality topics will be discussed in the EIR, rather than in the Initial Study (see Task 6, below).  Biological Resources – The Project site is within an urban setting and is bordered on all sides by the Menlo Park Labs campus and industrial/warehousing uses. Although the Project site is near the Bay and the Xxx Xxxxxxx San Francisco Bay National Wildlife Refuge, it is separated by Xxxxx Xxxxx 00 and, therefore, is not expected to have an impact on special-status species inhabiting these areas. The Project site is currently developed with buildings and surface parking lots. Trees line the southern of the Project site, along O’Brien Drive, which could provide habitat for nesting birds. The Initial Study would consider potential impacts to nesting birds during construction. This scope assumes that the applicant will provide a Biological Resources Assessment (BRA), per Mitigation Measure BIO-1 from the ConnectMenlo EIR. ICF will review the BRA and incorporate it into the Initial Study.
Sample 1Sample 2
Initial Study. Three years after the assumption of management by the Trust, the General Accounting Office shall conduct an interim study of the activities of the Trust and shall report the results of the study to the Committees of Congress. The study shall include, but shall not be limited to, details of programs and activities operated by the Trust and whether it met its obligations under this title.
Sample 1
Initial Study. All analyses used the Statistical Package for the Social Sciences (SPSS® 14 for Windows). Group data was reported using means (standard deviations) and ranges. The inter relationships between tender points and measures of disease activity were assessed using bivariate Xxxxxxxx’x correlations. To determine the factors influencing tender points, simple regression was followed by backwards stepwise multiple regression using tender points as the dependent variable. To determine the impact of tender points on patient outcomes, the patients were divided into two groups according to the number of positive tender points used in the diagnosis of fibromyalgia; those with 11 or more positive tender points and those with 10 or less positive tender points. To determine if tender minus swollen joint counts could identify fibromyalgic RA as accurately as tender points, Receiver Operator Characteristic (ROC) analysis was employed. ROC curve analyses are used in medicine to determine a cut-off value for a clinical test. This is a statistical approach to try and distinguish “normal” from “abnormal”. [Xxxxxx et al. 1994] The ROC curve is a graph of sensitivity vs.
Sample 1
Initial Study. Biosense shall be responsible for, or reimburse Rexahn for, as applicable, all costs of conducting the Initial Study other than the costs and expenses associated with the supply of RX-3117, which costs and expenses shall be allocated between the Parties in accordance with Section 2.6.
Sample 1
Initial Study. CONSULTANT shall perform an initial environmental study. The initial study shall follow the CITY’s initial study template found at the link xxxx://xxx.xxxxxxxxx.xxx/planning/eir/ConsultantPage.asp. Upon review of the initial study, the CITY’s Planning Department will determine the type of declaration or if an EIR is required. To complete the initial study, CONSULTANT shall complete the following: a. Prepare a project description. Include the effect of the PROJECT on utilities and service systems. b. Following the BAAQMD CEQA Guidelines, prepare an air quality study. c. Conduct a biological resources reconnaissance. It is assumed that no rare, threatened, endangered, or special status species of flora or fauna are known to inhabit the site. d. Because the portion of the PROJECT through which the 60-inch brick sewer traverses is partially landscaped, conduct a tree survey. e. Determine if any portion of the site is within an archaeologically sensitive area. If it is, prepare an archaeological report. Meet with the CITY’s Environmental Senior or Principal. f. Consult the CITY’s Historic Preservation Officer, to determine if buildings on the site are over 45 years old. Complete the Historic - Review Sheet 9-06 form. If a California Department of Parks and Recreation review is required, prepare a Primary Record and the Building, Structure and Object Record; complete the CITY's Xxxxxx Sheet; and prepare a cover letter summarizing the building’s significance and submit to the CITY’s Environmental Principal Planner. g. Incorporate from the geotechnical engineering report prepared in Task 4, the description of the geologic hazard zone or liquefaction zone as applicable and the Phase I site assessment for property along the proposed alignment which has a history of hazardous material use, such as industrial uses, gas stations, and/or farmland. h. Prepare a hydrology and water quality assessment that will allow quantification of the effect of storm water flow during the construction of the PROJECT and once it is complete. Prepare a pervious and impervious surfaces comparison. i. Confirm that the subject site is not located in an area that is protected by an adopted Habitat Conservation Plan, Natural Community Conservation Plan, or other approved local, regional, or state conservation plan. Prepare a summary memorandum. j. Conduct a site environmental noise study describing all residential and commercial areas where the existing noise levels are 60DNL or greater and a...
Sample 1
Initial Study. ICF Xxxxx & Xxxxxx would be responsible for preparing an IS to assist the City in determining the appropriate CEQA document for the proposed project. ICF Xxxxx & Xxxxxx would be responsible for preparing a Water Supply Assessment, the results of which would be summarized in the IS. Our subconsultant, Xxxx & Peers, would be responsible for preparing the traffic study, the results of which would be summarized in the IS. Our subconsultant, Tracer Environmental Sciences & Technologies, Inc., would be responsible for conducting the dispersion modeling to assess the offsite consequences of a chlorine release, the results of which would be incorporated Xx. Xxxx Xxxxxxx and Xx. Xxxxxx Xxxxxx October 24, 2008 into the IS. K2 Pure Solutions’ subconsultant, Yorke, would be responsible for conducting the air permitting work as well as for preparing the air quality section of the IS document. Our proposal is based on Yorke’s providing a complete air quality IS section (including a greenhouse gas emissions analysis) to ICF Xxxxx & Xxxxxx within one week of their receiving the project traffic study. The IS would be consistent in form and content with the California Office of Planning and Research Environmental Checklist Form in Appendix G of the CEQA Guidelines. ICF Xxxxx & Xxxxxx would prepare responses to each checklist question, which would include quantitative analyses of the proposed project’s air, noise, traffic, water supply, chlorine dispersion, and public utilities impacts. ICF Xxxxx & Xxxxxx would also prepare qualitative analyses of the project’s aesthetic, biological resources, cultural resources, geology and soils, hazards and hazardous materials, hydrology and water quality, land use and planning, mineral resources, public services, and recreation impacts. It is assumed that detailed analyses of the project’s construction and operational air quality analyses, including a health risk assessment, would be prepared by Yorke Engineering, LLC, under separate contract to K2 Pure Solutions. ICF Xxxxx & Xxxxxx staff would independently review the adequacy of the air quality analysis and health risk assessment on behalf of the City and would incorporate the results in the IS and CEQA documentation. It is also assumed that information on existing contamination and geotechnical conditions of the proposed project site would be provided by K2 Pure Solutions or DOW Chemical Company to ICF Xxxxx & Xxxxxx for use in completing the IS. ICF Xxxxx & Xxxxxx would prepare a bri...
Sample 1
AutoNDA by SimpleDocs
Initial Study. A study of a Completed Application conducted by the Transmission Provider (in coordination with the affected Transmission Owner(s)) in accordance with Section 19 or Section 32 of the Tariff.
Sample 1
Initial Study. The De Novo team will prepare an Initial Study (IS) to address potential impacts associated with the proposed project. The Initial Study would be prepared consistent with requirements of CEQA, and Appendix G of the CEQA Guidelines. This will specifically include: Project background, Description of project, Project setting, Affected Agencies, Environmental factors potentially affected, Environmental determination, Project and vicinity maps, Evaluation of environmental impacts (environmental checklist). We understand that the City has a conceptual plan and has requested a variety of technical studies to support an Initial Study/MND. These include: Phase 1 Environmental Study, Air Quality Impact Analysis, Biology Study, Extended XXXXX Records Search on all parcels, Historical resources evaluation, Geotechnical Report, Noise Study, Traffic Impact Study, and Water Supply Assessment. We have included all of these for use in the CEQA document; however, we recommend that a geotechnical report be prepared for a more specific design at the improvement plan phase of the project. We will instead into a planning level review of the soils within the boundary of the site. We feel that a design-level geotechnical evaluation should be done once more detail is known; however, at the request of the City we can add this as additional scope. Task 2.2
Sample 1

Related to Initial Study

  • Feasibility Study A feasibility study will identify the potential costs, service quality and other benefits which would result from contracting out the work in question. The cost analysis for the feasibility study shall not include the Employer’s indirect overhead costs for existing salaries or wages and benefits for administrative staff or for rent, equipment, utilities, and materials, except to the extent that such costs are attributable solely to performing the services to be contracted out. Upon completion of the feasibility study, the Employer agrees to furnish the Union with a copy if the feasibility study, the bid from the Apparent Successful Bidder and all pertinent information upon which the Employer based its decision to contract out the work including, but not limited to, the total cost savings the Employer anticipates. The Employer shall not go forward with contracting out the work in question if more than sixty percent (60%) of any projected savings resulting from the contracting out are attributable to lower employee wage and benefit costs.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Independent Study A sabbatical leave may be granted for a plan of independent study, research, writing, and/or travel equivalent in time and rigor to a sabbatical for formal study. A detailed, specific plan must be submitted by the applicant and approved by the Salary and Leaves Committee as likely to improve the applicant’s teaching effectiveness, strengthen the College’s academic program, or otherwise bring a clear benefit to students. In addition, sabbaticals for independent study must generate tangible products of use to students.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!